Skip to content

Evaluation of BIS for Quantification of Lymphedema

Evaluation of the Validity of BIS as a Tool for Quantification of Lymphedema Through Comparison With Perometry and Self-Report

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01544335
Enrollment
270
Registered
2012-03-05
Start date
2011-12-31
Completion date
2020-09-30
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The purpose of this study is to determine whether measuring the fluid in your arms using Bioimpedance Spectroscopy is as effective at detecting and monitoring lymphedema as measurements with the Perometer. The investigators will also evaluate any symptoms you may experience in your arms during and after treatment for breast cancer with a questionnaire.

Detailed description

During the study whenever you have an arm volume measurement using the Perometer, we will also measure the fluid in your arms using Bioimpedance Spectroscopy. These measurements are made by passing a harmless electrical signal of very low strength through your body to determine the difference in the amount of fluid in each arm. The test is simple and painless, and takes about 3 minutes. In addition, whenever you have an arm measurement, you will be asked to complete a questionnaire. While completing the questionnaire, you can skip any questions you do not wish to answer. The questionnaires will take about 10 minutes to complete. Arm measurements with the Perometer and Bioimpedance Spectroscopy and completion of the questionnaire will occur every 4-7 months when you are at MGH for regular medical visits.

Interventions

BIS used to measure fluid in arm

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically or cytologically confirmed invasive or in-situ carcinoma of the breast * Participants must have undergone sentinel node mapping or axillary dissection * Life expectancy of greater than 1 year. * Willingness to comply with required follow up Perometer and BIS measurements and completion of LEFT-BC questionnaire

Exclusion criteria

* Patients who have known metastatic disease or other locally advanced disease in the thoracic or cervical regions * Any patient who will not be returning routinely for follow-up at MGH or DFHCC * Participants with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events * History of primary lymphedema * History of prior surgery or radiation to the head, neck, upper limb, or trunk * Participants who have evidence that axillary lymph node malignancy is causing lymphedema due to recurrence as per physician discretion * Any patient who has bilateral lymph node mapping or dissection * Any patient with a current case of cellulitis * Patients with a history of a different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin

Design outcomes

Primary

MeasureTime frameDescription
Correlation of Impedance Ratios Obtained Through Bioimpedance Spectroscopy (BIS) With Perometric Relative Arm Volume Change (RVC)5 yearsCorrelation of volumetric measurements obtained using Perometry with impedance ratios obtained through BIS at the baseline examination and during follow-up visits. Impedance ratios will also be correlated with symptoms indicated in the LEFT-BC questionnaires completed during each examination. Volumetric arm measurements from perometry will be quantified using the RVC formula, which will be compared with impedance ratios calculated using the BIS device software.

Secondary

MeasureTime frameDescription
Compare Relationship Between Lymphedema Diagnostic Criteria Corresponding to BIS, Perometry, and Self-reported Symptoms5 yearsRelationship among diagnostic criteria pertaining to BIS, perometry, and self-reported symptoms. A change of \>3 Standard Deviations in impedance ratios compared to pre-surgical baseline is considered diagnostic for lymphedema when BIS is utilized. A relative volume change of \>5% - \>10% compared to baseline is considered lymphedema by perometry. Self-report of symptoms including feelings of swelling, heaviness, and tightness are often considered as criteria for lymphedema.

Countries

United States

Participant flow

Pre-assignment details

270 participants were accrued, however 65 had to be excluded because they later received bilateral breast surgery and 14 withdrew consent. This is why 191 participants started the study.

Participants by arm

ArmCount
Bioimpedance Spectroscopy
Subjects evaluated using Bioimpedance Spectroscopy Bioimpedance Spectroscopy: BIS used to measure fluid in arm
138
Total138

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyBaseline Measurements not Available19
Overall StudyDeath4
Overall StudyDisease progression3
Overall StudyLost to Follow-up27

Baseline characteristics

CharacteristicBioimpedance Spectroscopy
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
27 Participants
Age, Categorical
Between 18 and 65 years
111 Participants
Age, Continuous53.7 years
Race and Ethnicity Not Collected— Participants
Region of Enrollment
United States
138 participants
Sex: Female, Male
Female
138 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
4 / 191
other
Total, other adverse events
0 / 191
serious
Total, serious adverse events
0 / 191

Outcome results

Primary

Correlation of Impedance Ratios Obtained Through Bioimpedance Spectroscopy (BIS) With Perometric Relative Arm Volume Change (RVC)

Correlation of volumetric measurements obtained using Perometry with impedance ratios obtained through BIS at the baseline examination and during follow-up visits. Impedance ratios will also be correlated with symptoms indicated in the LEFT-BC questionnaires completed during each examination. Volumetric arm measurements from perometry will be quantified using the RVC formula, which will be compared with impedance ratios calculated using the BIS device software.

Time frame: 5 years

Population: 53 of the 191 participants had to be excluded. 27 lost to follow up, 4 died on the study, 3 had disease progression, and baseline measurements were not available for 19 participants.

ArmMeasureValue (NUMBER)
Bioimpedance SprectroscopyCorrelation of Impedance Ratios Obtained Through Bioimpedance Spectroscopy (BIS) With Perometric Relative Arm Volume Change (RVC)0.195 correlation coefficient
p-value: <0.001Correlation coefficient
Secondary

Compare Relationship Between Lymphedema Diagnostic Criteria Corresponding to BIS, Perometry, and Self-reported Symptoms

Relationship among diagnostic criteria pertaining to BIS, perometry, and self-reported symptoms. A change of \>3 Standard Deviations in impedance ratios compared to pre-surgical baseline is considered diagnostic for lymphedema when BIS is utilized. A relative volume change of \>5% - \>10% compared to baseline is considered lymphedema by perometry. Self-report of symptoms including feelings of swelling, heaviness, and tightness are often considered as criteria for lymphedema.

Time frame: 5 years

Population: This data was not collected and outcome cannot be reported.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026